JP2017523188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523188A5 JP2017523188A5 JP2017504752A JP2017504752A JP2017523188A5 JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5 JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- use according
- modification
- amino acid
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US62/032,430 | 2014-08-01 | ||
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US62/119,668 | 2015-02-23 | ||
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| US62/127,484 | 2015-03-03 | ||
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523188A JP2017523188A (ja) | 2017-08-17 |
| JP2017523188A5 true JP2017523188A5 (OSRAM) | 2018-09-13 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504752A Pending JP2017523188A (ja) | 2014-08-01 | 2015-07-31 | Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160032404A1 (OSRAM) |
| EP (1) | EP3185870A4 (OSRAM) |
| JP (1) | JP2017523188A (OSRAM) |
| KR (1) | KR20170042614A (OSRAM) |
| CN (1) | CN106714804A (OSRAM) |
| AU (1) | AU2015296010A1 (OSRAM) |
| BR (1) | BR112017001677A2 (OSRAM) |
| CA (1) | CA2955744A1 (OSRAM) |
| IL (1) | IL250221A0 (OSRAM) |
| MX (1) | MX2017001302A (OSRAM) |
| RU (1) | RU2017106794A (OSRAM) |
| SG (1) | SG11201700774UA (OSRAM) |
| WO (1) | WO2016019341A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450322B2 (en) | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
| TR201807039T4 (tr) | 2008-10-22 | 2018-06-21 | Array Biopharma Inc | Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri. |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| PT3699181T (pt) | 2014-11-16 | 2023-04-05 | Array Biopharma Inc | Forma cristalina de hidrogenossulfato de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| DK3892302T3 (da) | 2015-04-06 | 2023-11-13 | Janssen Pharmaceutica Nv | Sammensætninger indeholdende ibrutinib |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN109414442B (zh) | 2016-04-04 | 2024-03-29 | 洛克索肿瘤学股份有限公司 | 一种化合物的液体制剂 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| DK3800189T3 (da) | 2016-05-18 | 2023-07-31 | Loxo Oncology Inc | Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JP7356351B2 (ja) | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| EP3562796B1 (en) | 2016-12-30 | 2023-04-19 | Xcella Biosciences, Inc. | Multi-stage sample recovery system |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018225072A1 (en) | 2017-06-08 | 2018-12-13 | Enlivex Therapeutics Ltd. | Therapeutic apoptotic cells for cancer therapy |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| EP3806824A1 (en) * | 2018-06-15 | 2021-04-21 | Janssen Pharmaceutica NV | Formulations/compositions comprising ibrutinib |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| SG11202105309YA (en) * | 2018-11-30 | 2021-06-29 | Janssen Biotech Inc | Methods of treating follicular lymphoma |
| ES2987081T3 (es) | 2018-12-06 | 2024-11-13 | Xcella Biosciences Inc | Carga lateral de arreglos de microcapilares |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| EP4288565A4 (en) * | 2021-02-03 | 2025-04-23 | Curis, Inc. | BIOMARKERS FOR FIMEPINOSTAT THERAPY |
| US20230010803A1 (en) * | 2021-06-30 | 2023-01-12 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| MX2023015147A (es) * | 2021-06-30 | 2024-04-01 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| WO2025080543A1 (en) * | 2023-10-09 | 2025-04-17 | Bristol-Myers Squibb Company | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| JP7696987B1 (ja) | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101580714B1 (ko) * | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| US20130102477A1 (en) * | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| KR20230109775A (ko) * | 2011-10-19 | 2023-07-20 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
| JP2014532658A (ja) * | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| KR20250151610A (ko) * | 2012-06-04 | 2025-10-21 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| BR112015001690A2 (pt) * | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| BR112015014034A2 (pt) * | 2013-01-10 | 2017-07-11 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
-
2015
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523188A5 (OSRAM) | ||
| RU2017106794A (ru) | Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| Wang et al. | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies | |
| EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
| MY185845A (en) | Icos binding proteins | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| JP2014523751A5 (OSRAM) | ||
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| EP2568996A4 (en) | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES | |
| WO2017116817A3 (en) | Testing of medicinal drugs and drug combinations | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| EA202092156A1 (ru) | Модифицированные олигонуклеотиды и способы применения в лечении таупатий | |
| JP2017506259A5 (OSRAM) | ||
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| TWD195924S (zh) | 寶石 | |
| SI3857632T1 (sl) | Postopek obdelave katalizatorja iz zlitine platine, obdelanega katalizatorja iz zlitine platine in naprava za izvajanje postopka obdelave katalizatorja iz zlitine platine | |
| SG10201903424RA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| Zhang et al. | Heterocyclic compounds and uses thereof | |
| CO2019002853A2 (es) | Composiciones de tesofensina | |
| EP3733861A4 (en) | IN VITRO PROTEIN SYNTHESIS SYSTEM, KIT AND ITS PREPARATION PROCESS | |
| WO2016096640A3 (en) | Anti-cxcl12 antibody molecules and their uses | |
| PAUL | An In-depth Description and Detailed Analysis of Implementing Alternative Methods of Financing Software | |
| 王泽峰 | Extensive translation of circular RNAs driven by N6-methyladenosine | |
| To et al. | SARS-CoV infections in humans |